[HTML] nih.gov

[HTML][HTML] HES4 is a potential biomarker for bladder cancer: a Mendelian randomization study

Z Tan, X Chen, H Li, Y Huang, S Fu, M Ding… - Journal of …, 2024 - ncbi.nlm.nih.gov
Background: Patients with bladder cancer (BLCA) have a poor prognosis and little progress
has been made in treatment. Therefore, the purpose of this work was to employ Mendelian …
相关文章

HES4 is a potential biomarker for bladder cancer: a Mendelian randomization study

Z Tan, X Chen, H Li, Y Huang, S Fu, M Ding… - Journal of …, 2024 - europepmc.org
Background: Patients with bladder cancer (BLCA) have a poor prognosis and little progress
has been made in treatment. Therefore, the purpose of this work was to employ Mendelian …

HES4 is a potential biomarker for bladder cancer: a Mendelian randomization study

Z Tan, X Chen, H Li, Y Huang, S Fu… - Journal of …, 2024 - pubmed.ncbi.nlm.nih.gov
Background: Patients with bladder cancer (BLCA) have a poor prognosis and little progress
has been made in treatment. Therefore, the purpose of this work was to employ Mendelian …
[HTML] jcancer.org

[HTML][HTML] HES4 is a potential biomarker for bladder cancer: a Mendelian randomization study

Z Tan, X Chen, H Li, Y Huang, S Fu, M Ding, J Wang… - Journal of …, 2024 - jcancer.org
Background: Patients with bladder cancer (BLCA) have a poor prognosis and little progress
has been made in treatment. Therefore, the purpose of this work was to employ Mendelian …

HES4 is a potential biomarker for bladder cancer: a Mendelian randomization study.

Z Tan, X Chen, H Li, Y Huang, S Fu, M Ding… - Journal of …, 2024 - europepmc.org
Background: Patients with bladder cancer (BLCA) have a poor prognosis and little progress
has been made in treatment. Therefore, the purpose of this work was to employ Mendelian …